benzbromarone Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Benzbromarone is a uricosuric agent and non-competitive inhibitor of xanthine oxidase used in the treatment of gout, especially when allopurinol, a first-line treatment, fails or produces intolerable adverse effects. It is structurally related to the antiarrhythmic amiodarone.   Wikipedia

Chemistry

  • SMILES: CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1
  • InChIKey: WHQCHUCQKNIQEC-UHFFFAOYSA-N
  • Mol. Mass: 424.09
  • ALogP: 5.46
  • ChEMBL Molecules:
    benzbromarone  
    pyritinol  
More Chemistry

Pharmacology

Alternative names

2-ethyl-3-(3,5-dibrom-4-hydroxybenzoyl)benzofuran | 3,5-dibromo-4-hydroxyphenyl-2-ethyl-3-benzofuranyl ketone | azubromaron | benzbromaron | benzbromarone | desuric | l-2214 | mj-10061 | narcaricin mite

Organizations (14)

Research & Development (14)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (7)

Approved Indications (1)


 

Gout

Experimental Indications - Clinical Trial Phases 1-4 (7)


 

Diabetes Mellitus, Type 2 (Phase 4)

Familial Primary Pulmonary Hypertension (Phase 2)

Gout (Phase 3)

Heart Failure (Phase 4)

Heart Failure, Diastolic (Phase 4)

Hyperuricemia (Phase 4)

Metabolic Syndrome (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 10
  • # of Trial Organizations: 14

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue